Certain substituted spirocyclic lactams and use thereof as pharmaceuticals

Abstract

The present invention relates to novel 2-(6-oxo-1,7-diaza-spiro[4.4]non-7-yl)-propionamides of the formula wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m and p are as defined in the specification, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions containing them.

1 . A compound of the formula  
       
         
           
           
               
               
           
         
       
       wherein 
 R 1  is hydrogen or (C 1-4 )alkyl,  
 R 2  is optionally substituted (C 1-8 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, aryl or heteroaryl,  
 R 3  is —CH(R e )C(═O)N(R a )R b  or —(CH 2 ) k N(R c )R d , wherein 
 k is 0, 1 or 2,  
 R a , R b , R c  and R d , independently, are hydrogen or an optionally substituted (C 1-8 )alkyl, (C 5-9 )bicycloalkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, aryl, aryl(C 1-4 )alkyl, heteroaryl, heteroaryl(C 1-4 )alkyl, 4-chromanyl, 1,2,3,4-tetrahydro-quinolin-4-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, thiochroman-4-yl-1,1-dioxide, 4-isochromanyl, 1,2,3,4-tetrahydro-isoquinolin-4-yl, thioisochroman-4-yl-1,1-dioxide, 1,1-dioxo-1,2,3,4-tetrahydro-1lambda*6*-benzo[e][1,2]thiazin-4-yl, 1,1-dioxo-3,4-dihydro-1H-1lambda*6*-benzo[c][1,2]oxathiin-4-yl, 2,2-dioxo-1,2,3,4-tetrahydro-2lambda*6*-benzo[c][1,2]thiazin-4-yl or 2,2-dioxo-3,4-dihydro-2H-2lambda*6*-benzo[e][1,2]oxathiin-4-yl group, or  
 R a  and R b , or R c  and R d , together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl group, and  
 R e  is (C 1-8 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, (C 3-7 )cycloalkyl or (C 3-7 )cycloalkyl(C 1-4 )alkyl,  
 
 R 4  is hydrogen or an optionally substituted (C 1-8 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, (C 2-6 )alkenyl, (C 2-6 )alkynyl, (C 3-7 )cycloalkoxy(C 1-4 )alkyl or aryl group,  
 R 5  is hydrogen or optionally substituted (C 1-4 )alkyl,  
 R 6  is hydrogen, hydroxy or halogen, and  
 m and p, independently, are 1 or 2,  
 in free base form or in acid addition salt form.  
 
     
     
         2 . A process for the preparation of a compound as defined in  claim 1  of the formula I, in free base form or in acid addition salt form, comprising the steps of acylating a compound of the formula  
       
         
           
           
               
               
           
         
       
       wherein R 1 , R 2  and R 3  are as defined for the formula I, with an acid of the formula  
       
         
           
           
               
               
           
         
       
       wherein R 4 , R 5 , R 6 , m and p are as defined for the formula I, or an activated form, such as an ester or an acid halogenide, thereof and recovering the so obtainable compound of the formula I in free base form or in acid addition salt form.  
     
     
         3 . A compound according to  claim 1 , in free base form or in pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.  
     
     
         4 . A compound according to  claim 1 , in free base form or in pharmaceutically acceptable acid addition salt form, for use in the treatment of neurological or vascular disorders related to beta-amyloid generation and/or aggregation.  
     
     
         5 . A pharmaceutical composition comprising a compound as claimed in  claim 1 , in free base form or in pharmaceutically acceptable acid addition salt form, as active ingredient and a pharmaceutical carrier or diluent.  
     
     
         6 . The use of a compound as claimed in  claim 1 , in free base form or in pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of neurological or vascular disorders related to beta-amyloid generation and/or aggregation.  
     
     
         7 . The use of a compound as claimed in  claim 1 , in free base form or in pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of neurological or vascular disorders related to beta-amyloid generation and/or aggregation.  
     
     
         8 . A method for the treatment of neurological or vascular disorders related to beta-amyloid generation and/or aggregation in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound as claimed in  claim 1 , in free base form or in pharmaceutically acceptable acid addition salt form.  
     
     
         9 . A combination comprising a therapeutically effective amount of a compound as claimed in  claim 1 , in free base form or in pharmaceutically acceptable acid addition salt form, and a second drug substance, for simultaneous or sequential administration.  
     
     
         10 . The use of a compound as claimed in  claim 1 , in free base form or in pharmaceutically acceptable acid addition salt form, as histopathological labeling agent, imaging agent and/or biomarker for the selective labeling of the beta-secretase cleaving enzyme BACE.